Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | EYA2 | O00167 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL1742779 | 1.00 | BLM (0.68) | BLMPMP22HSD17B10TDP1EYA2 | |
| SCHEMBL2770982 | 0.94 | BLM (0.76) | BLMPMP22HSD17B10TDP1EYA2 | |
| SCHEMBL3831965 | 0.92 | BLM (0.80) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL657586 | 0.91 | BLM (0.77) | BLMPMP22HSD17B10TDP1EYA2 | |
| SCHEMBL15508717 | 0.90 | BLM (0.69) | BLMPMP22HSD17B10TDP1EYA2 | |
| Ethylene Glycol SCHEMBL6500129 | 0.90 | BLM (0.83) | BLMPMP22HSD17B10TDP1EYA2 | |
| Ethylene Glycol SCHEMBL5335726 | 0.90 | BLM (0.83) | BLMPMP22HSD17B10TDP1EYA2 | |
| Hydrochloric Acid SCHEMBL15516229 | 0.89 | BLM (0.67) | BLMPMP22HSD17B10TDP1EYA2 | |
| Egtazic Acid SCHEMBL3631773 | 0.88 | BLM (0.87) | BLMPMP22HSD17B10TDP1EYA2 | |
| SCHEMBL958878 | 0.87 | BLM (0.56) | BLMPMP22HSD17B10TDP1EYA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377548-B1 | PROCESS FOR NITRATING PHOTOCLEAVABLE COMPOUNDS | MEDICAL RES COUNCIL (GB) | 2009-02-18 | — | — | EP | claimed |
| US-20050181363-A1 | Method of effecting lysis of acid-fast bacteria and method of performing gene amplification or detection therewith | ARKRAY, INC. (JP) | 2005-08-18 | — | — | US | claimed |
| US-20040171846-A1 | Process for nitrating photocleavable compounds | MEDICAL RESEARCH COUNCIL (GB) | 2004-09-02 | — | — | US | claimed |
| US-6037457-A | RECOVERING RECOMBINANT BLOOD GLYCOPROTEIN; PROPAGATING MAMMALIAN CELLS IN NUTRIENTS, RECOVERING A PORTION OF THE CULTURE, CONCENTRATING THE BLOOD GLYCOPROTEIN, PURIFYING THE BLOOD GLYCOPROTEIN BY CHROMATOGRAPHY | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-03-14 | — | — | US | claimed |
| EP-3947375-B1 | IMIDAZOLONYLQUINOLINE COMPOUNDS AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2024-04-03 | — | — | EP | disclosed |
| US-20210055188-A1 | METHODS FOR ISOLATING, DETECTING, AND/OR ANALYZING ANTIBODIES FROM A FORMALIN FIXED PARAFFIN EMBEDDED (FFPE) TISSUE SAMPLE | SHIMADZU CORPORATION (JP) | 2021-02-25 | — | — | US | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| US-8744778-B2 | Methods for characterizing agonists and partial agonists of target molecules | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8535941-B2 | Lipophilic dye-based FRET assays for clostridial toxin activity | ALLERGAN, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8497081-B2 | Botulinum toxin screening assays | ALLERGAN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-0486214-A2 | Putrescine N-methyltransferase, recombinant DNA molecules encoding putrescine N-methyltrasferase, and transgenic tobacco plants with altered nicotine content | Philip Morris Products Inc. (US) | 1992-05-20 | — | — | EP | disclosed |
| EP-0466199-A1 | Polypeptide fragments of factor VIIIc, corresponding probes and DNA sequences and DNA constructs | CHIRON CORPORATION (US) | 1992-01-15 | — | — | EP | disclosed |
| US-5063245-A | Hormone inhibitors | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-11-05 | — | — | US | disclosed |
| US-5045455-A | DNA sequences, genetic engineering, blood coagulants, hemophilia | CHIRON CORPORATION (US) | 1991-09-03 | — | — | US | disclosed |
| US-5004804-A | Method and composition for preparation of factor VIIIC | NORDISK GENTOFTE (DK) | 1991-04-02 | — | — | US | disclosed |
| US-4851450-A | GLYCEROLS MONOETHERIFIED WITH VICINAL DIHYDROXYALKYL OR DIACETOXYALKYL | DEMOPOULOS CONSTANTINE A (GR) | 1989-07-25 | — | — | US | disclosed |
| US-4785008-A | ANTIINFLAMMATORY AGENTS | LABORATOIRES CHAUVIN-BLACHE (FR) | 1988-11-15 | — | — | US | disclosed |
| EP-0150735-A2 | Protein composition exhibiting coagulation activity and method for the preparation thereof | CHIRON CORPORATION (US) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | BLM 4486/4885PMP22 4228/4885HSD17B10 879/4885 |
| US-20040171846-A1 | Process for nitrating photocleavable compounds | NOS2, SOD1, NIT2 | BLM 2089/4885PMP22 2141/4885HSD17B10 2983/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | BLM 4435/4885PMP22 4047/4885HSD17B10 885/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | BLM 4486/4885PMP22 4228/4885HSD17B10 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.